'Sustained remission' in a case of SLE following megadose cyclophosphamide

Lupus

Volumn 8, Issue 1, 1999, Pages 77-80

  Mittal, G ^a   Balakrishna, C ^a   Mangat, G ^a   Joshi, V R ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

Cyclophosphamide; Nephritis; Remission; SLE

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; DRUG MEGADOSE; DRUG OVERDOSE; FEMALE; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; PANCYTOPENIA; PRIORITY JOURNAL; REMISSION; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TIME FACTORS;

EID: 0032969683     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847326     Document Type: Article

References (34)

1. Hahn BH. Management of systemtic lupus erythematosus, In: Kelley WN, Harris ED, Ruddy S. Sledge CB (eds). Text Book of Rheumatology. Philadelphia: WB Saunders, 1993, pp 1043-1055.
2. Berden JHM. Lupus nephritis in Nephrology Forum. Kidney Int 1997; 52: 538-558.
3. Moroni G, Banfi G, Ponticelli C. Clinical status of patients after 10 years of lupus nephritis. Q J Med 1992; 84: 681-689.
4. Pickering G, et al. Treatment of systemic lupus erythematosus with steroids. Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J 1961; 2: 915-912.
5. Ginzler EM, et al. A multicenter study of outcome of systemic lupus erythematosus. Early variables as predictor of progress. Arthritis Rheum 1982; 25: 601-611.
6. Rothfield NF. Systemic lupus erythematosus: clinical aspects and treatment. In: McCarty DJ, Koopman WJ (eds). Arthritis and Allied Conditions - A Textbook of Rheumatology. Philadelphia: Lea & Febiger, 1993, pp 1155-1178.
7. Austin HA III, et al. Therapy for lupus nephritis. Controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
8. Esdaile JM, et al. The clinical and renal biopsy predictors of long term outcome in lupus nephritis. Q J Med 1989; 72: 779-833.
9. Ponticelli C, et al. Long term prognosis of diffuse lupus nephritis. Clin Nephrol 1987; 28: 263-271.
10. Cameron JS et al. Systemic lupus erythematosus with nephritis a long term study. Q J Med 1979; 48: 1-24.
11. Steinberg AD, Steinberg SC. Long term preservatin of renal function with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritus Rhem 1991; 34: 945-950.
12. McCune WJ, Golb J, Zeldes W. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe SLE. N Engl J Med 1988; 318: 1423-1431.
13. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisolone over prednisone alone in lupus nephritis. N Engl J Med 1984; 311: 1528-1533.
14. Barlow JE et al. Effect of treatment on evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311: 491-495.
15. Cameron JS. What is the role of long term cytotoxic agents in the treatment of lupus nephritis? Nephrology 1993; 6: 172-176.
16. Balow JE, Austin HA, Tsokos GC. Lupus nephritis. Ann Intern Med 1987; 106: 79-94.
17. Van Den Wall AWL, et al. Therapy of proliferative lupus glomerulonephritis: a prospective trial in Netherlands. Neth J Med 1994; 45: 280-284.
18. Boumpas DT, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
19. Donadio JF, et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151.
20. Ciruelo E, De La Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028-2034.
21. Boumpas DT, et al. Systemic lupus erythematosus: emerging concepts. Part 1. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995; 122: 940-950.
22. Shoenfeld Y, Krause I, Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis 1997; 56: 1-7.
23. Van Bruggen MCJ, et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/pr mice. Kidney Int 1996; 50: 1555-1564.
24. Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiological changes in murine systemic lupus erythematosus (abstract). Arthritis Rheum 1994; 37: 289-297.
25. Coma D, et al. Mycophenolate mofetil prolongs life survival in murine lupus autoimmune disease (abstract). J Am Soc Nephrol 1995; 6: 825.
26. Takabhayashi K, et al. Effect of FK 506, a novel immunosuppressive drug on murine systemic lupus erythematosus (abstract). Clin Immunol Immunopathol 1989; 51: 110-117.
27. Isenberg Da, Shoenfeld Y, Schwartz RS. Multiple serologic reactions and their relationship to clinical activity in SLE. Arthritis Rheum 1984; 27: 132.
28. Fauci AS, Young KR. Immunoregulatory agents. In: Kelley WN, Harris ED, Ruddy, S, Sledge CB (eds). Text Book of Rheumatology. Philadelphia, WB Saunders, 1993: pp 797-821.
29. Colvin M. Cyclophosphamide and analogues. In: Crooke St, Perstayko A W (eds), Cancer and Chemotherapy. New York: Academic Press, 1981, p 25.
30. Raptis G, et al. The addition of paclitaxel (TXL) to high dose cyclophosphamdie (CTX) + filgrastrim (G-CSF) markedly enhances mobilization of CD34 + peripheral blood proginator cells (PBPC) in patients with responding metastatic breast cancer (MBC) undergoing high dose chemotherapy (Abstract 919). Proc Am Soc Clin Oncol 1995; 14: 313.
31. Kessinger A, Bierman PJ, Vose JM, Armitage JO. High-dose cyclophosphamide, carmustine and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322.
32. Avash L, et al. High dose multimodality therapy with autologous stem cell support for stage III B breast cancer: the DFCI/BIH experience (Abstract). Proc Am Soc Clin Oncol 1995; 14: 318.
33. Santos GW, et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Eng J Med 1983; 309: 1347.
34. Smith BR, et al. Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following marrow transplantation of transfused patients with aplastic anaemia. Transplantation 1985; 39: 631.